Glipizide Mechanism and Clinical Considerations

Primary Mechanism

Glipizide, a sulfonylurea, binds to specific receptors on pancreatic β-cells, stimulating the release of insulin from the pancreas, and can reduce HbA1c levels by 1.0% to 1.5% in patients with type 2 diabetes 1

The American Diabetes Association notes that glipizide may cause weight gain, similar to other sulfonylureas, and hypoglycemia is the most common adverse effect, particularly in elderly patients and those with liver or kidney dysfunction 1
Newer-generation sulfonylureas like glipizide may have a lower risk of hypoglycemia compared to older agents, as suggested by the American Association of Clinical Endocrinologists 2

The European Association for the Study of Diabetes notes that metformin works by reducing hepatic glucose output and improving insulin resistance, differing from glipizide's mechanism of action 3
The American College of Endocrinology states that thiazolidinediones (TZDs) increase insulin sensitivity in target tissues, contrasting with glipizide's insulin secretion stimulation 4
The International Diabetes Federation mentions that glinides also stimulate insulin secretion but have a shorter duration of action compared to glipizide 5
The American Gastroenterological Association notes that α-glucosidase inhibitors reduce postprandial blood glucose by inhibiting carbohydrate absorption, a distinct mechanism from glipizide's 5

As monotherapy, glipizide reduces HbA1c by an average of 1 percentage point, consistent with most diabetes medications used as single agents 6, 7
When combined with metformin, glipizide provides an additional 1.0 percentage point reduction in HbA1c (mean difference 1.00 percentage point [95% CI, 0.75 to 1.25]) compared to metformin alone 6, 7

Glipizide causes weight gain, averaging 2.7 kg more than metformin monotherapy 6, 7

Avoid using glipizide as preferred therapy in patients with established cardiovascular disease or chronic kidney disease, where SGLT2 inhibitors or GLP-1 receptor agonists offer superior cardiovascular and renal protection 8
Recognize that newer agents (GLP-1 RAs, SGLT2 inhibitors) may provide similar or superior HbA1c reduction without the risks of hypoglycemia and weight gain associated with sulfonylureas 6, 7, 8